New Indication for Abraxane

26 Oct 2012 10:31 AM | Lori Aubrey (Administrator)
NEW Indication Announcement for ABRAXANE® for Injectable Suspension
(paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

Celgene Corporation is pleased to announce that ABRAXANE is now approved for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Read more on our FDA Approval Page.


Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software